One of the key mechanisms by which prostate cancer cells evade hormone therapy is through intratumor testosterone production. New evidence points toward androstenedione as a potential precursor of intratumor androgen production and furthers nomination of AKR1C3 as a therapeutic target in advanced disease. Clin Cancer Res; 20(21); 5343-5. ©2014 AACR.
Recommended CitationKnudsen, Karen E, "Hormone whodunit: clues for solving the case of intratumor androgen production." (2014). Department of Cancer Biology Faculty Papers. Paper 69.